CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 144 enrolled
Drug / intervention
Naproxen +1 moredrug
Likely dose
Naproxen 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03771612
NCT03771612Early Ph 1Completed
CompareCT.gov

Inflammation and Daily Life Study

University of California, Los Angeles·interventional·Posted Dec 11, 2018·Updated Feb 25, 2025

In Brief

A Early Phase 1 clinical trial evaluating Naproxen and Placebos for Inflammation. Completed, enrolled 144 participants across 1 site.

Detailed Summary

UCLA researchers looking for healthy individuals (age 45-60) to participate in a study investigating whether an anti-inflammatory medication can impact daily life experiences. Everyday for two weeks, participants will take either an anti-inflammatory medication (naproxen) twice daily, or a placebo pill twice daily. Participants will also answer daily questions during the 2-week period. Participants will also fill out questionnaires and complete a few tasks on the computer: once prior to the 2-week period and once immediately after the 2-week period, both during online study sessions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedDec 11, 2018
Enrollment StartFeb 9, 2022
Primary CompletionNov 9, 2023
Study CompletionJun 21, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.6 years ago

Interventions

Naproxendrug

Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)

Placebosdrug

Half of the participants will be randomly assigned to receive a placebo pill twice daily